Organisation paid for research Program year 2025 Source: CMS Open Payments

Washington University Medicine Admin

Neither a doctor nor a teaching hospital

Research payments

$5,545,252

53 payments

Through program year 2025, Washington University Medicine Admin is reported as receiving $5,545,252 in research payments, across 53 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $1,643,729 35
2024 Research $2,564,962 10
2023 Research $1,336,561 8

Breakdown

Who paid Research payments · program years 2023–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $5,308,693 51 payments
  2. Biogen, Inc. $236,559 2 payments
Studies the money was for Research payments · program years 2023–2025
  1. FIH Dose escalation ph1 DLL3 pos SCLC and other NEC $1,596,573 1 payment
  2. A First in Human Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 764532 administered by parenteral route in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3 $1,328,726 10 payments
  3. FIH Dose escalation ph1 DLL3 pos SCLC and other NE $1,059,152 1 payment
  4. A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Longitudinal Natural History Run-in and Open-Label Extension $236,559 2 payments
  5. Phase II/III Brigimadlin in 1st L DD Liposarcoma $108,003 1 payment
  6. Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma $92,682 12 payments
  7. Brightline-4 $80,572 1 payment
  8. PDE4 Phase III trial in IPF patients $78,831 2 payments
  9. Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma $68,151 7 payments
  10. Phase II III BI 907828 + BI 754091 in 1st L DD Lip $58,855 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record